Current concepts in antibiotic-resistant Gram-negative bacteria

Expert Review of Anti-Infective Therapy

Volumn 5, Issue 5, 2007, Pages 833-843

  Torres, Julián Andrés ^a   Villegas, Maria Virginia ^a   Quinn, John P ^b  

^a International Center for Medical Research and Training   (Colombia)

^b Chicago Infectious Disease Research Institute   (United States)

Author keywords

Bacterial resistance; Carbapenems; Gram negatives; Mechanisms of resistance; Tigecycline

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; METICILLIN; OUTER MEMBRANE PROTEIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PIPERACILLIN; PORIN; TETRACYCLINE DERIVATIVE; TIGECYCLINE; UNINDEXED DRUG;

ACINETOBACTER; AEROMONAS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CITROBACTER FREUNDII; COAGULASE NEGATIVE STAPHYLOCOCCUS; ENTEROBACTER; ENTEROBACTERIACEAE; ENZYME MODIFICATION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL INFECTION; HUMAN; HYDROLYSIS; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MEDICAL DECISION MAKING; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; PROTEUS; PROVIDENCIA RETTGERI; PROVIDENCIA STUARTII; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; REVIEW; SALMONELLA; SEIZURE; SERRATIA; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; BIOLOGICAL TRANSPORT; CARBAPENEMS; CELL MEMBRANE PERMEABILITY; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS; INTENSIVE CARE UNITS; MUTATION; PORINS; SENTINEL SURVEILLANCE;

EID: 35348982873     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/14787210.5.5.833     Document Type: Review

References (92)

1. Jones RN. Resistance patterns among nosocomial pathogens: trends over the past few years. Chest 119 (Suppl. 2). 397S-404S (2001).
2. Livermore DM. The threat from the pink corner. Ann. Med. 35(4), 226-234 (2003).
3. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32(8), 470-485 (2004).
4. Sader HS, Bledenbach DJ, Jones RN. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin. Respir. Crit. Care Med. 24(1), 121-134 (2003).
5. Rhomberg P, Jones RN, Mutnick A. Geographic variations and trends in key bacteremic pathogen resistance (R): report from the SENTRY Antimicrobial Surveillance Program (1997-2001). Presented at: Proceedings of the 42nd. Interscience Congress of Antimicrobial Agents and Chemotherapy. CA, USA, September 17-30, 2002.
6. Deshpande LM, Jones RN, Fritsche TR, Sader HS. Occurrence and characterization of carbapenemase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program (2000-2004). Microb. Drug Resist. 12(4), 223-230 (2006).
7. Robicsek A, Strahilevitz J, Sahm DF, Jacoby GA, Hooper DC. qnr prevalence in ceftazidime-resistant Enterobacteriaceae isolates from the United States. Antimicrob. Agents Chemother. 50(8), 2872-2874 (2006).
8. Park CH, Robicsek A, Jacoby GA, Sahm D, Hooper DC. Prevalence in the United States of aac(6)-lb-cr encoding a ciprofloxacin- modifying enzyme. Antimicrob. Agents Chemother. 50(11), 3953-3955 (2006).
9. Aeschlimann JR. The role of multidrug efflux pumps in the antibiotic resistance of Pseudomonas aeruginosa and other Gram-negative bacteria. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 23(7), 916-924 (2003).
10. Phiiippon A, Arlet G, Jacoby GA. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46, 1-11 (2002).
11. Jacoby GA, Munoz-Price LS. The new β-lactamases. N. Engl. J. Med. 352(4), 380-391 (2005).
12. Livermore DM. β-lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8, 557-584 (1995).
13. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among Gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289(7), 885-888 (2003).
14. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin. Microbiol. Rev. 18(4), 657-686 (2005).
15. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob. Chemother. 59(2), 165-174 (2007).
16. Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid-mediated extended-spectrum β-lactamase (CTX-M-3 like) from India and gene association with insertion sequence. ISEcp1. FEMS Microbiol. Lett. 201(2), 237-241 (2001).
17. Rice LB. Challenges in idenfying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and [Pseudomonas aeruginosa. Clin. Infect. Dis. 43(Suppl. 2), S100-S105 (2006).
18. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin. Micrabiol Infec. 8(6). 321-331 (2002).
19. Yigit H, Queenan AM, Anderson GJ et al. Novel carbapenem-hydrolyzing betalactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae Antimicrob. Agents Chemother. 45, 1151-1161 (2001).
20. Miriagou V, Tzouvelekis LS, Rossiter S, Tzelepi E, Angulo FJ, Whichard JM. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob. Agents Chemother. 47(4), 1297-1300 (2003).
21. Smittr ME, Hanson ND, Herrera VL et al. Plasmid-mediated, carbapenem-hydrolysing β-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J. Antimicrob. Cbemother. 51 (3), 711-714 (2003).
22. Woodford N, Tierno PM Jr, Young K et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob. Agents Chemother. 48(12), 4793-4799 (2004).
23. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob. Agents Cbemother. 49(10), 4423-4424 (2005).
24. Bratu S, Landman D, Alam M, Tolentino E, Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob Agents Chemother. 49(2), 776-778 (2005).
25. Hong T, Moland ES, Abdalhamid B et al. Escherichia coli. development of carbapenem resistance during therapy. Clin. Infect. Dis. 40(10), e84-e86 (2005).
26. Villegas MV, Lolans K, Correa A, Kattan JN, Lopez JA, Quinn JP. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lactamase. Antimicrob. Agents Chemother. 51(4), 1553-1555 (2007).
27. Heritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, Nordmann P, Characterization of the naturally occurring oxacillinase of Acinetobacter baumannii. Antimicrob. Agents Cbernother. 49(10), 4174-4179 (2005).
28. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii. mechanisms and epidemiology. Clin. Microbiol. Infect. 12(9), 826-836 (2006).
29. Villegas MV, Kattan JN, Correa A et al. Dissemination of Acinetobacter baumannii clones with OXA-23 carbapenemase in Colombian Hospitals. Antimicrob Agents Chemother. 51 (6), 2001-2004 (2007).
30. Coelho JM, Woodford N, Warner M et al. Spread of two OXA-23-producing Acinetobacter baumannii clones in England. Presented at: The 6th International Symposium on the Biology of Acinetobacter. Dublin, Ireland. September 15-17, 2004. p. 19 (Abstract C3).
31. Boo TW, Walsh F, Crowley B. First report of OYA-23 carbapenemase in clinical isolates of Acinetobacter species in the Irish Republic. J. Antimicrob. Chemother. 58(5), 1101-1102 (2006).
32. Naas T, Levy M, Hirschauer C, Marchandin H, Nordmann P. Outbreak of carbapenem-resistant Acinetobacter barimannii producing the carbapenemase OXA-23 in a tertiary care hospital of Papeete, French Polynesia. J. Clin. Microbiol. 43(9). 4826-4829 (2005).
33. Dalla-Costa LM, Coelho JM, Souza HA et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J. Clin. Microbiol. 41(7), 3403-3406 (2003).
34. Jeong SH, Bae IK, Park KO et al. Outbreaks of imipenem-resistant Acinetobacter baumannii producing carbapenemases in Korea. J. Microbiol. 44(4), 423-431 (2006).
35. Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baummannii isolates producing the carbapenemase OXA-40. Antimicrob. Agents Chemother. 50(9), 2941-2945 (2006).
36. Da Silva GJ, Quinteira S. Bertolo E et al. Long-term dissemination of an OXA-40 carbapenemase-producing Acinetobacter baumannii clone in the Iberian Peninsula. J. Antimicrob. Chemother. 54(1), 255-258 (2004).
37. Lopez-Otsoa F, Gallego L, Towner KJ, Tysall L, Woodford N, Livermore DM. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J. Clin. Microbiol. 40(12), 4744-4743 (2002).
38. Bertini A, Giordano A, Varesi P, Villa L, Mancini C, Carattoli A. First report of the carbapenem-hydrolyzing oxacillinase OXA-58 in Acinetobacter baumannii isolates in Italy. Antimicrob. Agents Chermother. 50(6), 2268-2269 (2006).
39. Heritier C, Dubouix A, Poirel L, Marty N, Nordmann P. A nosocomial outhbreak of Acinobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J. Antimicrob. Chemother. 55(1), 115-118 (2005).
40. Coelho J. Woodford N, Afzal-Shah M, Livermore D. Occurrence of OXA-58-like carbapenemases in Acinobacter spp. collected over 10 years in three continents. Antimicrob. Agents Chemother. 50(2), 756-758 (2006).
41. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-β-lactamases: the quiet before the storm? Clin. Microbiol. Rev. 18(2), 306-325 (2005).
42. Kassis-Chikhani N, Decre D, Gautier V et al. First outbreak of multidrug-resistant Klebsiella pneumoniae carrying blaVIM-1 and blaSHV-5 in a French university hospital. J. Antimicrob. Chemother: 57(1), 142-145 (2006).
43. Yan JJ, Ko WC, Chuang CL, Wu JJ. Metallo-β-lactamase-producing Enterobacteriaceae isolates in a university hospital in Taiwan: prevalence of IMP-8 in Enterobacter cloacae and first identification of VIM-2 in Citrobacter freundii. J. Antimicrob. Cheimother. 50(4), 503-511 (2002).
44. Livermore DM, Woodford N. The β-liactamase threat in Enterobacteriaceae, Pseudomonas and Acinetabacter. Trends Microbiol. 14(9),413-420 (2006).
45. Poirel L, Nordmann P. Acquired carbapenem-hydrolyzing β-lactamases and their genetic support. Curr. Pharm. Biotechnol. 3(2), 117-127 (2002).
46. Poirel L, Naas T Nicolas D et al Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob. Agents Chemother. 44(4), 891-897 (2000).
47. Crespo MP, Woodford N, Sinclair A et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-β-lactamase, in a tertiary care center in Cali, Colombia. J. Clin. Microbiol. 42(11), 5094-5101 (2004).
48. Cornaglia G, Mazzariol A, Lauretti L, Rossolini GM, Fontana R. Hospital outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-1, a novel transferable metallo-β-lactamase. Clin. Infect. Dis. 31(5), 1119-1125 (2000).
49. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-β-lactamase (VIM-2) in the United States. Antimicrob. Agents Chemother. 49(8), 3538-3540 (2005).
50. Villegas MV, Lolans K, del Rosario OM et al. First detection of metallo-β-tactamase VIM-2 in Pseudomonas aeruginosa isolates from Colombia. Antimicrob. Agents Chemother. 50(1), 226-229 (2006).
51. Dery KJ, Soballe B, Witherspoon MS et al. The aminoglycoside 6′-N-acetyltransferase type Ib encoded by Tn1331 is evenly distributed within the cell's cytoplasm. Antimicrob. Agents Chemother. 47(9), 2897-2902 (2003).
52. Robicsek A, Strahilevitz J, Jacoby GA et al. Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase. Nat. Med. 12(1), 83-88 (2006).
53. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. Clin. Infect. Dis. 45(1), 88-94 (2007).
54. Depardieu F, Podglajen I, Leclercq R, Collatz E, Courvalin P. Modes and modulations of antibiotic resistance gene expression. Clin. Microbiol. Rev. 20(1), 79-114 (2007).
55. Poole K. Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. Curr. Pharm. Biotechnol. 3(2), 77-98 (2002).
56. Marchand I, Damier-Piolle L, Courvalin P, Lambert T. Expression of the RND-type efflux pump AdeABC in Acinobacter baumannii is regulated by the AdeRS two-component system. Antimicrob. Agents Chemother. 48(9), 3298-3304 (2004).
57. Hocquet D, Nordmann P, El GF, Cabanne L, Plesiat P. Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginasa. Antimicrob. Agents Chemother. 50(4), 1347-1351 (2006).
58. Wolter DJ, Smith-Moland E, Goering RV, Hanson ND, Lister PD. Multidrug resistance associated with mexXY expression in clinical isolates of Pseudomonas aeruginosa from a Texas hospital. Diagn. Microbial. Infect. Dis. 50(1), 43-50 (2004).
59. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudamonas aeruginosa. Antimicrob. Agents Chemother. 44(12), 3322-3327 (2000).
60. Kohler T, Michea-Hamzehpour M, Henze U, Gotoh N, Curty LK, Pechere JC. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of Pseudomonas aeruginosa. Mol. Microbiol. 23(2), 345-354 (1997).
61. Chuanchuen R, Narasaki CT, Schweizer HP. The MexJK efflux pump of Pseudomonas aeruginosa requires OprM for antibiotic efflux but not for efflux of triclosan. J. Bacteriol. 184(18), 5036-5044 (2002).
62. Poole K, Gotoh N, Tsujimoto H et al. Overexpression of the mexC-mexD-oprJ efflux operon in nfxB-type multidrug-resistant strains of Pseudomonas aeruginosa. Mol. Microbiol. 21(4), 713-724 (1996).
63. Li XZ, Zhang L, Poole K. SmeC, an outer membrane multidrug efflux protein of Stenotrophomonas maltophilia. Antimicrob. Agents Chermother. 46(2), 333-343 (2002).
64. Yamane K, Wachino JI, Suzuki S et al. New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Eicherichia coli clinical isolate. Antimicrob. Agents Chemother. 51(9), 3354-3360 (2007).
65. Quinn JP, Dudek EJ, DiVincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenern during therapy for Pseudomonas aeruginosa infections. J. Infect. Dis. 154(2), 289-294 (1986).
66. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34(5), 634-640 (2002).
67. Vila J, Marti S, Sanchez-Cespedes J. Porins, efflux pumps and multidrug resistance in Acinetobacter baumannii. J. Antimicrob. Chemother. 59(6), 1210-1215 (2007).
68. Gribun A, Nitzan Y, Pechatnikov I, Hershkovits G, Katcoff DJ. Molecular and structural characterization of the HMP-AB gene encoding a pore-forming protein from a clinical isolate of Acinenobacter baumannii. Curr. Microbiol. 47(5), 434-443 (2003).
69. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol. Mol. Biol. Rev. 67(4), 593-656 (2003).
70. del Mar TM, Beceiro A, Perez A et al. Cloning and functional analysis of the gene encoding the 33- to 36-kilodalton outer membrane protein associated with carbapenem resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49(12), 5172-5175 (2005).
71. Siroy A, Molle V, Lemaitre-Guillier C et al. Channel formation by CarO, the carbapenem resistance-assoclated-outer membrane protein of Acinetobacter, baumannii. Anntimicrob. Agents Chemother 49(12), 4876-4883 (2005).
72. Dupont M, Pages JM, Lafitte D, Siroy A, Bollet C. Identification of an OprD bomologue in Acinetobacter baumannii. J. Proteome Res. 4 (6), 2386-2390 (2005).
73. Poole K. Resistance to β-lactam antibiotics. Cell. Moll. Life Sci. 61(17), 2200-2223 (2004).
74. Endtz HP, Ruijs GJ, van Klingeren B, Jansen WH, van der RT, Mouton RP. Quinolone resistance in campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J. Antimicrob. Chemother. 27(2), 199-208 (1991).
75. Wang M, Sahm DF, Jacoby GA, Hooper DC. Emerging plasmid-mediated quinolone-resistance associated with the qnr gene in [Klebsiella pneumoniae clinical isolates in the-United States. Antimicrob. Agents Chemother. 48(4), 1295-1299 (2004).
76. Martinez-Martinez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 351 (9105), 797-799 (1998).
77. Mammeri H, Van De LM, Poirel L, Martinez-Martinez L, Nordmann P. Emergence of plasmid-mediated quinolone resistance in Escherichia coli in Europe, Antimicrob. Agents Chemother. 49(1), 71-76 (2005).
78. Jonas D, Biehier K, Hartung D, Spitzmuller B, Daschner FD. Plasmid-mediated quinolone resistance in isolates obtained in German intensive care units. Antimicrob. Agents Chemother. 49(2), 773-775 (2005).
79. Poirel L, Leviandier C, Nordmann R Prevalence and genetic analysis of plasmid-mediated quinolone resistance determinants QnrA and QnrS in Enterobacteriaceae isolates from a French university hospital. Antimicrob. Agents Chemother. 50(12), 3992-3997 (2006).
80. Tran JH, Jacoby GA, Hooper DC. Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV. Antimirob. Agents Chemother. 49(7), 3050-3052 (2005).
81. Robicsek A, Sahm, DE, Strahilevitz J. Jacoby GA, Hooper DC. Broader distribution of plasmid-mediated quinolone resistance in the United States. Antimicrob. Agents Chemother. 49(7), 3001-3003 (2005).
82. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin. Infect. Dis. 38(9), 1279-1286 (2004).
83. Fritsche TR, Stilwell MG, Jones RN. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). Clin. Microbiol. Infect. 11 (12), 974-984 (2005).
84. Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J. Antimicrob. Chemother. 52(3), 331-344 (2003).
85. Jones RN, Huynh HK, Biedenbach DJ, Fritsche, TR, Sader HS. Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations. J. Antimicrob. Chemother. 54(1), 144-154 (2004).
86. Mushtaq S, Ge Y, Livermore DM. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential. Antimicrob. Agents Chemother. 48(8), 3086-3092 (2004).
87. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology222(1-2), 114-124 (2006).
88. Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob. Agents Chemother 47 (1), 400-404 (2003). %
89. Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn. Microbiol. Infect. Dis. 57(4), 423-428 (2007).
90. Navon-Venezia S, Leavitt A, Carneli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 59(4), 772-774 (2007).
91. Peleg AY, Adams J, Paterson DL. Tigecycline efflux as a mechanism for non-susceptibility in Acinetobacter baumannii. Antimicrob. Agents Chemother. 51(6). 2065-2069(2007).
92. Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J. Clin. Microbiol. 45(1), 227-230 (2007).